Researchers have discovered and validated a blood test that can predict with greater than 90 percent accuracy if a healthy person will develop mild cognitive impairment or Alzheimer's disease within three years. Described in a Nature Medicine article published online on March 9, 2014, the study heralds the potential for developing treatment strategies for Alzheimer's at an earlier stage, when therapy would be more effective at slowing or preventing onset of symptoms. It is the first known published report of blood-based biomarkers for preclinical Alzheimer's. The test identifies 10 lipids, or fats, in the blood that predict disease onset. It could be ready for use in clinical studies in as few as two years and, researchers say, other diagnostic uses are possible. "Our novel blood test offers the potential to identify people at risk for progressive cognitive decline and can change how patients, their families, and treating physicians plan for and manage the disorder," says the study's corresponding author Howard J. Federoff, M.D., Ph.D., professor of neurology and executive vice president for health sciences at Georgetown University Medical Center. There is no cure or effective treatment for Alzheimer's. Worldwide, approximately 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer's by 2050. Dr. Federoff explains there have been many efforts to develop drugs to slow or reverse the progression of Alzheimer's disease, but all of them have failed. He says one reason may be the drugs were evaluated too late in the disease process. "The preclinical state of the disease offers a window of opportunity for timely disease-modifying intervention," Dr. Federoff says.Login Or Register To Read Full Story